文献速递心脑血管急症重症综合管理与镇静镇痛

长期护理机构心房颤动居民停用抗凝后的卒中与出血风险

Stroke and Bleeding Risk in Long-Term Care Residents With Atrial Fibrillation Who Discontinue Anticoagulation.
PubMed 文献 · JAMA Netw Open · 2026-10-01
一句话结论目标试验模拟显示,长期护理机构房颤居民停用抗凝与继续抗凝的卒中风险(sHR 1.07,95%CI 0.93-1.23)和出血风险(sHR 1.02,95%CI 0.92-1.13)相似,但停用者死亡风险更高(HR 1.27,95%CI 1.23-1.31)。

该研究采用目标试验模拟与克隆-删失加权(CCW)分析,基于2020—2021年美国长期护理机构(LTC)服务Medicare受益人的理赔数据,纳入2020年4月1日至12月31日进入LTC且正在接受抗凝治疗的房颤患者,排除有抗凝额外指征(如人工心脏瓣膜或静脉血栓栓塞症)者,比较停用抗凝与继续抗凝的策略。共纳入15 426例LTC居民(平均[SD]年龄82.6[7.6]岁,女性62.6%)。停用抗凝者发生187例卒中、297例出血事件、3684例死亡(平均[SD]随访128.9[177.9]天);继续抗凝者发生321例卒中、493例出血事件、5475例死亡(平均[SD]随访279.6[204.9]天)。停用抗凝者卒中风险(sHR 1.07;95%CI 0.93-1.23)和出血风险(sHR 1.02;95%CI 0.92-1.13)与继续抗凝者相似,但死亡风险更高(HR 1.27;95%CI 1.23-1.31)。作者认为,极高的死亡率、未测量的混杂因素以及依赖理赔数据判定结局,可能限制了更好地理解停用抗凝对卒中与出血的后果。

要点

  • 在LTC房颤居民中,停用抗凝者卒中风险与继续抗凝者相似(sHR 1.07;95%CI 0.93-1.23),出血风险亦相似(sHR 1.02;95%CI 0.92-1.13)。
  • 停用抗凝者死亡风险高于继续抗凝者(HR 1.27;95%CI 1.23-1.31)。
  • 停用抗凝者平均随访128.9(177.9)天,发生187例卒中、297例出血、3684例死亡;继续抗凝者平均随访279.6(204.9)天,发生321例卒中、493例出血、5475例死亡。
  • 该研究采用目标试验模拟与克隆-删失加权分析,纳入15 426例LTC房颤居民,平均年龄82.6(7.6)岁,女性占62.6%。
  • 作者指出,极高的死亡率、未测量的混杂因素以及依赖理赔数据判定结局,可能限制了更好地理解停用抗凝对卒中与出血的后果。

适用人群与场景

  • 美国长期护理机构中正在接受抗凝治疗的Medicare受益人房颤患者,于2020年4月1日至12月31日进入长期护理机构。
  • 排除有抗凝额外指征者,包括人工心脏瓣膜或静脉血栓栓塞症。

研究设计与关键结果

  • 研究类型:比较效果研究,采用目标试验模拟与克隆-删失加权(CCW)分析,数据为2020—2021年美国LTC机构服务Medicare受益人的理赔数据。
  • 样本量:共纳入15 426例LTC居民,平均(SD)年龄82.6(7.6)岁,女性占62.6%。
  • 暴露:停用抗凝 vs 继续抗凝。
  • 主要终点:停用抗凝者卒中风险与继续抗凝者相似(sHR 1.07;95%CI 0.93-1.23),出血风险亦相似(sHR 1.02;95%CI 0.92-1.13)。
  • 死亡:停用抗凝者死亡风险高于继续抗凝者(HR 1.27;95%CI 1.23-1.31)。
  • 事件数:停用抗凝者发生187例卒中、297例出血事件、3684例死亡,平均(SD)随访128.9(177.9)天;继续抗凝者发生321例卒中、493例出血事件、5475例死亡,平均(SD)随访279.6(204.9)天。

证据类型、等级与局限

  • 证据类型:目标试验模拟(比较效果研究),采用克隆-删失加权分析。
  • 局限:极高的死亡率、未测量的混杂因素以及依赖理赔数据判定结局,可能限制了更好地理解停用抗凝对卒中与出血的后果。

对床旁实践的改变

  • 作者认为,在LTC房颤居民中,停用抗凝与继续抗凝相比,未伴随更高的卒中或出血风险,但停用者死亡风险更高(HR 1.27;95%CI 1.23-1.31)。
  • 极高的死亡率、未测量的混杂因素以及依赖理赔数据判定结局,可能限制了更好地理解停用抗凝对卒中与出血的后果。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Atrial fibrillation (AF) leads to more than 100 000 cases of stroke yearly and is particularly prevalent in long-term care (LTC) residents. Anticoagulation (AC) is the mainstay of stroke prevention, but given its risks, clinicians and residents may consider discontinuation at the time of LTC entry.

OBJECTIVE: To estimate the association between AC discontinuation and stroke and bleeding risk among LTC residents with AF.

DESIGN, SETTING, AND PARTICIPANTS: This comparative effectiveness research study with target trial emulation used claims data (2020-2021) from LTC facilities in the US serving Medicare beneficiaries. Medicare beneficiaries with AF receiving AC who entered LTC between April 1 and December 31, 2020, were included; those with additional indications for AC, including prosthetic heart valve or venous thromboembolism, were excluded. Analysis was performed in August 2026.

EXPOSURE: Discontinuer vs continuer assignment.

MAIN OUTCOMES AND MEASURES: The main outcomes were stroke (including ischemic stroke, transient ischemic attack, and systemic embolism) and bleeding, assessed using Medicare claims. A target trial emulation was conducted with clone censor weighting (CCW) analysis. Specifically, eligible LTC residents were assigned (cloned) to each of 2 strategies: AC discontinuation or AC continuation. Clones were then censored when they deviated from their assigned strategy, and inverse probability of censoring weighting was applied to address informative censoring: residents who deviated differing systematically from those who did not. Subdistribution hazard ratios (sHRs) for stroke and bleeding were then calculated to account for competing mortality and a cause-specific hazard ratio (HR) for death.

RESULTS: This study included 15 426 LTC residents (mean [SD] age, 82.6 [7.6] years). Most were female (62.6%). AC discontinuers had 187 strokes, 297 bleeding events, and 3684 deaths over a mean (SD) of 128.9 (177.9) days. AC continuers had 321 strokes, 493 bleeding events, and 5475 deaths over a mean (SD) of 279.6 (204.9) days. Discontinuers had similar stroke risk (sHR, 1.07; 95% CI, 0.93-1.23) and bleeding risk (sHR, 1.02; 95% CI, 0.92-1.13) compared with continuers, but discontinuers had higher mortality risk (HR, 1.27; 95% CI, 1.23-1.31).

CONCLUSIONS AND RELEVANCE: In this target trial emulation with CCW in a cohort of LTC residents with AF, AC discontinuation was not associated with higher stroke or bleeding risk. Very high mortality, unmeasured confounding, and reliance on claims-based outcome ascertainment may have limited the ability to better understand the consequences of AC discontinuation on stroke and bleeding.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Kapoor A, Chen Z, Patel J, et al. Stroke and Bleeding Risk in Long-Term Care Residents With Atrial Fibrillation Who Discontinue Anticoagulation. JAMA Netw Open. 2026. PMID: 42931771. doi:10.1001/jamanetworkopen.2026.40964

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。